Crispr Therapeutics had its Relative Strength (RS) Rating upgraded from 68 to 71 Thursday -- a welcome improvement, but still shy of the 80 or higher score you prefer to see.
When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
IBD's unique rating identifies share price action with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the last 52 weeks holds up against all the other stocks in our database.
History shows that the stocks that go on to make the biggest gains typically have an 80 or better RS Rating as they launch their largest runs. See if Crispr Therapeutics can continue to show renewed price strength and hit that benchmark.
See How IBD Helps You Make More Money In Stocks
Crispr Therapeutics is trying to complete a consolidation with an 87.05 buy point. See if the stock can break out in volume at least 40% higher than normal.
The company reported negative growth for both sales and earnings last quarter.
Crispr Therapeutics earns the No. 217 rank among its peers in the Medical-Biomed/Biotech industry group. Genmab and Vertex Pharmaceuticals are also among the group's highest-rated stocks.
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks
